Neogap Therapeutics

Executive Summary

Neogap Therapeutics is a Swedish biotech developing personalized cell therapies for cancer patients with limited treatment options. Founded in 2019, the company's lead program is a novel autologous cell therapy that trains a patient's own immune cells to recognize and eliminate tumor cells, offering a tailor-made approach for each individual. Currently in Phase 1 clinical trials, Neogap aims to address significant unmet needs across multiple solid tumors. The company's innovative platform utilizes proprietary antigen presentation and T-cell activation technologies, potentially enabling robust anti-tumor responses with reduced off-target effects. With a strong intellectual property portfolio and a seasoned management team, Neogap is poised to contribute to the next wave of cancer immunotherapies. The early clinical data are anticipated to provide proof-of-mechanism and safety validation, which are critical for advancing the program and attracting strategic partnerships or additional financing. Despite the early stage, the personalized nature of the therapy and the growing interest in cell-based treatments position Neogap favorably within the competitive landscape. Successful completion of the Phase 1 trial could unlock significant value and pave the way for expedited development in selected indications.

Upcoming Catalysts (preview)

• Q2 2027Phase 1 interim safety and efficacy data readout60% success
• Q4 2026Initiation of Phase 2 trial planning and regulatory interactions70% success
• TBDPotential partnership or licensing deal with a larger pharma40% success